Cancer treatment and research最新文献_第10页

RNA Modifications in Cancer Stem Cell Biology. 癌症干细胞生物学中的 RNA 修饰。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_2

Jonas Cerneckis, Qi Cui, Wei Liu, Yanhong Shi

引用次数: 0

Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer. 免疫检查点抑制剂：治疗三阴性乳腺癌的新途径

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-33602-7_2

Ouissam Al Jarroudi, Khalid El Bairi, Giuseppe Curigliano, Said Afqir

引用次数: 0

The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience. 全球乳腺癌药物获取情况：ONCOLLEGE 的经验。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-33602-7_14

Csongor György Lengyel, Baker Shalal Habeeb, Sara Cecilia Altuna, Dario Trapani, Shah Zeb Khan, Sadaqat Hussain

引用次数: 0

Recent Advances in RNA m⁶A Modification in Solid Tumors and Tumor Immunity. 实体瘤和肿瘤免疫中 RNA m6A 修饰的最新进展。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_4

Michelle Verghese, Emma Wilkinson, Yu-Ying He

{"title":"Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity.","authors":"Michelle Verghese, Emma Wilkinson, Yu-Ying He","doi":"10.1007/978-3-031-45654-1_4","DOIUrl":"10.1007/978-3-031-45654-1_4","url":null,"abstract":"An analogous field to epigenetics is referred to as epitranscriptomics, which focuses on the study of post-transcriptional chemical modifications in RNA. RNA molecules, including mRNA, tRNA, rRNA, and other non-coding RNA molecules, can be edited with numerous modifications. The most prevalent modification in eukaryotic mRNA is N6-methyladenosine (m6A), which is a reversible modification found in over 7000 human genes. Recent technological advances have accelerated the characterization of these modifications, and they have been shown to play important roles in many biological processes, including pathogenic processes such as cancer. In this chapter, we discuss the role of m6A mRNA modification in cancer with a focus on solid tumor biology and immunity. m6A RNA methylation and its regulatory proteins can play context-dependent roles in solid tumor development and progression by modulating RNA metabolism to drive oncogenic or tumor-suppressive cellular pathways. m6A RNA methylation also plays dynamic roles within both immune cells and tumor cells to mediate the anti-tumor immune response. Finally, an emerging area of research within epitranscriptomics studies the role of m6A RNA methylation in promoting sensitivity or resistance to cancer therapies, including chemotherapy, targeted therapy, and immunotherapy. Overall, our understanding of m6A RNA methylation in solid tumors has advanced significantly, and continued research is needed both to fill gaps in knowledge and to identify potential areas of focus for therapeutic development.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"190 ","pages":"95-142"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic (De)regulation in Prostate Cancer. 前列腺癌的表观遗传（去）调控。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_10

Chenxi Xu, Shuai Zhao, Ling Cai

引用次数: 0

Hinduism. 印度教。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-29923-0_16

Purvi Patel

引用次数: 0

Islam. 伊斯兰教。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-29923-0_18

Mona Mojtahedzadeh, Hassan Qureshi

引用次数: 0

Targeting ATR in Cancer Medicine. 靶向ATR在癌症医学中的应用。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-30065-3_14

Carolina Salguero, Christian Valladolid, Helen M R Robinson, Graeme C M Smith, Timothy A Yap

{"title":"Targeting ATR in Cancer Medicine.","authors":"Carolina Salguero, Christian Valladolid, Helen M R Robinson, Graeme C M Smith, Timothy A Yap","doi":"10.1007/978-3-031-30065-3_14","DOIUrl":"10.1007/978-3-031-30065-3_14","url":null,"abstract":"As a key component of the DNA Damage Response, the Ataxia telangiectasia and Rad3-related (ATR) protein is a promising druggable target that is currently widely evaluated in phase I-II-III clinical trials as monotherapy and in combinations with other rational antitumor agents, including immunotherapy, DNA repair inhibitors, chemo- and radiotherapy. Ongoing clinical studies for this drug class must address the optimization of the therapeutic window to limit overlapping toxicities and refine the target population that will most likely benefit from ATR inhibition. With advances in the development of personalized treatment strategies for patients with advanced solid tumors, many ongoing ATR inhibitor trials have been recruiting patients based on their germline and somatic molecular alterations, rather than relying solely on specific tumor subtypes. Although a spectrum of molecular alterations have already been identified as potential predictive biomarkers of response that may sensitize to ATR inhibition, these biomarkers must be analytically validated and feasible to measure robustly to allow for successful integration into the clinic. While several ATR inhibitors in development are poised to address a clinically unmet need, no ATR inhibitor has yet received FDA-approval. This chapter details the underlying rationale for targeting ATR and summarizes the current preclinical and clinical landscape of ATR inhibitors currently in evaluation, as their regulatory approval potentially lies close in sight.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"186 ","pages":"239-283"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polycomb Repressive Complex 2 in Oncology. 肿瘤学中的多聚酶抑制复合体 2。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_9

Yiran Guo, Yao Yu, Gang Greg Wang

引用次数: 0

Recent Advances of RNA m⁶A Modifications in Cancer Immunoediting and Immunotherapy. 癌症免疫编辑和免疫疗法中 RNA m6A 修饰的最新进展。

Cancer treatment and research Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_3

Shoubao Ma, Tasha Barr, Jianhua Yu

{"title":"Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy.","authors":"Shoubao Ma, Tasha Barr, Jianhua Yu","doi":"10.1007/978-3-031-45654-1_3","DOIUrl":"10.1007/978-3-031-45654-1_3","url":null,"abstract":"Cancer immunotherapy, which modulates immune responses against tumors using immune-checkpoint inhibitors or adoptive cell transfer, has emerged as a novel and promising therapy for tumors. However, only a minority of patients demonstrate durable responses, while the majority of patients are resistant to immunotherapy. The immune system can paradoxically constrain and promote tumor development and progression. This process is referred to as cancer immunoediting. The mechanisms of resistance to immunotherapy seem to be that cancer cells undergo immunoediting to evade recognition and elimination by the immune system. RNA modifications, specifically N6-methyladenosine (m6A) methylation, have emerged as a key regulator of various post-transcriptional gene regulatory processes, such as RNA export, splicing, stability, and degradation, which play unappreciated roles in various physiological and pathological processes, including immune system development and cancer pathogenesis. Therefore, a deeper understanding of the mechanisms by which RNA modifications impact the cancer immunoediting process can provide insight into the mechanisms of resistance to immunotherapies and the strategies that can be used to overcome such resistance. In this chapter, we briefly introduce the background of cancer immunoediting and immunotherapy. We also review and discuss the roles and mechanisms of RNA m6A modifications in fine-tuning the innate and adaptive immune responses, as well as in regulating tumor escape from immunosurveillance. Finally, we summarize the current strategies targeting m6A regulators for cancer immunotherapy.","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"190 ","pages":"49-94"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0